Synlett 2018; 29(16): 2203-2207
DOI: 10.1055/s-0037-1609623
letter
© Georg Thieme Verlag Stuttgart · New York

Iridium/f-Amphox-Catalyzed Asymmetric Hydrogenation of Styrylglyoxylamides

Simin Wang
a   Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China   Email: wenjl@sustc.edu.cn   Email: zhangxm@sustc.edu.cn
,
Yuena Yu
a   Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China   Email: wenjl@sustc.edu.cn   Email: zhangxm@sustc.edu.cn
,
a   Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China   Email: wenjl@sustc.edu.cn   Email: zhangxm@sustc.edu.cn
b   Academy for Interdisciplinary Studies, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China
,
Xumu Zhang*
a   Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China   Email: wenjl@sustc.edu.cn   Email: zhangxm@sustc.edu.cn
c   Shenzhen Grubbs Institute, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, 518055, P. R. of China
› Author Affiliations
We thank the Shenzhen Basic Research Free Exploration Fund (JCYJ20170817104853520) and Shenzhen Peacock Plan (KQTD2015071710315717) from the Shenzhen Commission of Science, Technology and Innovation.
Further Information

Publication History

Received: 28 April 2018

Accepted after revision: 30 July 2018

Publication Date:
20 August 2018 (online)


Abstract

We report an iridium-catalyzed asymmetric hydrogenation reaction for the preparation of chiral homophenylalanine derivatives. Catalyzed by an iridium/f-amphox complex, the asymmetric hydrogenation of styrylglyoxylamides was conducted smoothly with turnover numbers of up to 10,000 and up to 98% ee. This method was successfully applied in a synthesis of a fragment of benazepril, a drug used for the treatment of high blood pressure.

Supporting Information

 
  • References and Notes

  • 1 Parmley WW. Am. J. Med. 1998; 105: 27S
    • 2a Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. N. Engl. J. Med. 2006; 354: 131
    • 2b Frampton JE, Peters DH. Drugs 1995; 49: 440
    • 2c Chrysant SG, Chrysant GS. Expert Rev. Cardiovasc. Ther. 2003; 1: 345
    • 2d Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Cardiovasc. Drug Rev. 2004; 22: 189
    • 2e McCormack PL, Keating GM. Drugs 2006; 66: 961
  • 3 Ahmad AL, Oh PC, Abd Shukor SR. Biotechnol. Adv. 2009; 27: 286
    • 4a Blaser H.-U, Jalett HP, Wiehl J. J. Mol. Catal. 1991; 68: 215
    • 4b Blaser U.-H, Jalett H.-P, Spindler F. J. Mol. Catal. A: Chem. 1996; 107: 85
    • 4c Blaser H.-U, Studer M. Acc. Chem. Res. 2007; 40: 1348
  • 5 The Handbook of Homogeneous Hydrogenation . de Vries JG, Elsevier CJ. Wiley-VCH; Weinheim: 2008
  • 6 Wu W, Liu S, Duan M, Tan X, Chen C, Xie Y, Lan Y, Dong X.-Q, Zhang X. Org. Lett. 2016; 18: 2938
  • 7 Yu J, Long J, Yang Y, Wu W, Xue P, Chung LW, Dong X.-Q, Zhang X. Org. Lett. 2017; 19: 690
  • 8 Yu J, Duan M, Wu W, Qi X, Xue P, Lan Y, Dong X.-Q, Zhang X. Chem. Eur. J. 2017; 23: 970
  • 9 Zhao B, Han Z, Ding K. Angew. Chem. Int. Ed. 2013; 52: 4744
  • 10 Denmark SE, Fan Y. J. Org. Chem. 2005; 70: 9667
  • 11 CCDC 1862847 contains the supplementary crystallographic data for compound 2g. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
  • 12 Thaper RK, Kumar Y, De S, Kumar DS. M. WO 02076375, 2002
  • 13 Asymmetric Hydrogenation of Styrylglyoxylamides 1ar; General ProcedureIn an argon-filled glove box, a 10 mL vial was charged with [Ir(COD)Cl]2 (4.0 mg, 5.9 ×10–3 mmol), f-amphox (7.3 mg, 13.1 × 10–3 mmol), and anhyd i-PrOH (3 mL). The mixture was stirred for 2 h at 25 °C to give an orange-red solution. The resulting solution (50 μL, c = 4 × 10–3 mmol/mL) and a solution of KOH in i-PrOH (40 μL, c = 0.05 mmol/mL) were transferred by a syringe into a 5 mL vial charged with the appropriate α-keto β-enamide (0.2 mmol) in DCE (2 mL). The vial was transferred to an autoclave, which was then charged with 20 atm of H2 and the mixture was stirred at r.t. for 12 h. The hydrogen gas was released slowly in a well-ventilated hood, and the solution was passed through a short column of silica gel to remove the metal complex. The product was analyzed by 1H NMR for conversion, and the ee was determined by HPLC.
  • 14 (S,3E)-N-(tert-Butyl)-2-hydroxy-4-phenylbut-3-enamide (2c)White solid; yield: 46 mg (99%; conversion: 99%; 98% ee); mp 71–74 °C; [α]D 24 –7.8 (c 0.5, MeOH). HPLC: Chiracel AD-3 column [254 nm, 25 °C, hexane–i-PrOH (80:20); flow: 1.0 mL/min]; t R 1 = 4.0 min, t R 2 = 4.4 min. 1H NMR (400 MHz, CDCl3): δ = 7.36–7.29 (m, 2 H), 7.25 (dd, J = 9.9, 4.7 Hz, 2 H), 7.21–7.15 (m, 1 H), 6.65 (d, J = 15.9 Hz, 1 H), 6.18 (dd, J = 15.9, 7.0 Hz, 1 H), 5.97 (s, 1 H), 4.51 (d, J = 6.9 Hz, 1 H), 3.52 (s, 1 H), 1.29 (s, 9 H). 13C NMR (101 MHz, CDCl3): δ = 171.5, 136.3, 132.6, 128.6, 128.0, 127.4, 126.8, 73.0, 51.4, 28.8. HRMS-ESI: m/z [M + Na]+ calcd for C14H19NNaO2: 256.1305; Found: 256.1308.